Source: Neuromuscular Disorders. Conference titles: International Congress of the World Muscle Society. Unidades: FMVZ, ICB, FZEA
Subjects: FARMACOLOGIA, CÃO GOLDEN RETRIEVER, DISTROFIA MUSCULAR ANIMAL, NEUROLOGIA VETERINÁRIA
ABNT
ARAÚJO, Karla Patrícia Cardoso et al. Treatment with bortezomib (PS-341) of Golden Retriever Muscular Dystrophy (GRMD): analysis of proteasome inhibition and morphology of dystrophic skeletal muscle. Neuromuscular Disorders. Oxford: Elsevier Science. Disponível em: https://doi.org/10.1016/j.nmd.2009.06.218. Acesso em: 03 nov. 2024. , 2009APA
Araújo, K. P. C., Moreira, D. F., Gaiad, T. P., Miglino, M. A., Górniak, S. L., Feder, D., et al. (2009). Treatment with bortezomib (PS-341) of Golden Retriever Muscular Dystrophy (GRMD): analysis of proteasome inhibition and morphology of dystrophic skeletal muscle. Neuromuscular Disorders. Oxford: Elsevier Science. doi:10.1016/j.nmd.2009.06.218NLM
Araújo KPC, Moreira DF, Gaiad TP, Miglino MA, Górniak SL, Feder D, Belizário JE, Ambrósio CE. Treatment with bortezomib (PS-341) of Golden Retriever Muscular Dystrophy (GRMD): analysis of proteasome inhibition and morphology of dystrophic skeletal muscle [Internet]. Neuromuscular Disorders. 2009 ; 19( 8-9): 613.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.nmd.2009.06.218Vancouver
Araújo KPC, Moreira DF, Gaiad TP, Miglino MA, Górniak SL, Feder D, Belizário JE, Ambrósio CE. Treatment with bortezomib (PS-341) of Golden Retriever Muscular Dystrophy (GRMD): analysis of proteasome inhibition and morphology of dystrophic skeletal muscle [Internet]. Neuromuscular Disorders. 2009 ; 19( 8-9): 613.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.nmd.2009.06.218